07 July 2023
07 July 2023
With its ascites treatment device completing 1,000 implants, the company now eyes an imminent heart failure trial.
The trials will be conducted in the UK and focus on treating cancer.
A slowed cognitive decline of 38% was reported in patients treated with simufilam for six months compared to placebo.
Vaxart has announced that both groups dosed with the oral bivalent vaccine candidate showed increased antibody responses to norovirus.
Four members were hospitalised, including one from the low dose group and the remaining from placebo.
Reducing the oesophageal intraepithelial infiltration of mast cells is the primary endpoint of the study.
The study will assess ST-067 in combination with Merck’s KEYTRUDA.
Patients with moderate-to-severe pain after abdominal surgery are enrolled in the study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
